UK's Lymphoma Association Taps Homeopath

The Lymphoma Association, one of the leading lymphoma organizations in the UK, has appointed Sally Penrose as its new Chief Executive, a controversial choice earning understandable criticism from respected UK-based science bloggers.

What about Penrose is disconcerting? Simple: Her background is not with organizations founded on sound scientific principles—like the Lymphoma Association—but with two large homeopathic organizations:

The first is the British Homeopathy Association (BHA), the purpose of which is to "promote homeopathy practised by doctors and other healthcare professionals." They "strongly believe that homeopathy should be fully integrated into the healthcare system and available as a treatment choice for everyone."

The second is the Faculty of Homeopathy, a product of Parliament which serves as the "professional body for doctors and other healthcare professionals who have qualified in homeopathy and incorporate it into their everyday practice."

The suggestion by the BHA that it isn't a treatment choice is nonsense—information about homeopathic remedies is available all over the internet. Why should doctors be asked to integrate it into their practices if they don't think it's an effective treatment modality?

Homeopathy lacks the kind of rigorous research mentality that informs the scientific community, and tends to be no better than a placebo, making Penrose a dubious choice whose leadership has the potential to subvert the credibility of the organization.

Addendum: the BHA lists 'conditions with positive evidence', medical conditions which they claim homeopathy has proven to be an effective treatment. Not a single mention of cancer on that list, much less any mention of lymphomas.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap